Immunotherapy News and Research

Latest Immunotherapy News and Research

Melanomas express B7-H1 protein to hide from T-cells

Johns Hopkins and Yale scientists have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. Nearly 40 percent of their sampling of melanoma tissues contained the B7-H1 protein, also called PD-L1, and scientists say it could be used as a target for new therapies.

26 Apr 2012

Elan first quarter total revenue increases 17% to $288.4 million

Elan Corporation, plc, today reported its first quarter 2012 financial results.

26 Apr 2012

OncoSec reports positive interim data from ElectroChemotherapy Phase IV head and neck cancer study

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe.

23 Apr 2012

New genetic signature may predict NSCLC patients at risk of relapse

A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.

19 Apr 2012

Study demonstrates how Parkinson's disease protein can spread in patient's brain

Last year, researchers from the Perelman School of Medicine at the University of Pennsylvania found that small amounts of a misfolded brain protein can be taken up by healthy neurons, replicating within them to cause neurodegeneration. The protein, alpha-synuclein (a-syn), is commonly found in the brain, but forms characteristic clumps called Lewy bodies, in neurons of patients with Parkinson's disease (PD) and other neurodegenerative disorders.

18 Apr 2012

Immunotherapy may also help elderly cancer patients

Cancer is much more likely in the elderly than the young, and their bodies often are less prepared to fight the disease and the often-toxic side effects of treatment.

16 Apr 2012

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest is seeking marketing approval in Canada for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

10 Apr 2012

Advaxis, Karolinska Institutet enter collaboration to develop cat allergy vaccine

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a research collaboration with Professor Marianne van Hage, research group leader and Head of the Clinical Immunology and Allergy Unit and Vice Head of the Department of Medicine at Karolinska Institutet in Stockholm, Sweden.

6 Apr 2012

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine.

5 Apr 2012

Nuvilex realizes important role for Cell-in-a-Box technology

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions through acquisition of SG Austria assets, realizes the important role for Cell-in-a-Box technology and aims to bring to light its use in the production of therapeutic antibodies for clinically important diseases.

4 Apr 2012

New paradigm for immunotherapy against cancer

Scientists may have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

2 Apr 2012

Galectin Therapeutics fourth quarter net loss increases to $3.7 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2011.

31 Mar 2012

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

The National Comprehensive Cancer Network (NCCN) held the NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care, March 14 - 18 at The Westin Diplomat in Hollywood, Florida. The latest updates in clinical practice decision-making in cancer care were presented, including, but not limited to, the new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening and updates to the NCCN Guidelines for Melanoma and Non-Hodgkin's Lymphomas.

29 Mar 2012

OncoSec Medical closes sale of 31,000,000 shares of common stock in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.

29 Mar 2012

NY-ESO-1 vaccine shows promise against ovarian cancer, melanoma

An immunotherapy regimen incorporating poxviruses and targeting a particular tumor antigen, NY-ESO-1, has shown promise in treating two types of cancers.

27 Mar 2012

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology.

27 Mar 2012

OncoSec to purchase $7.75M of securities in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase $7.75 million of securities in a registered public offering.

26 Mar 2012

Researchers pinpoint new mechanism that potently activates T-cells in leprosy

UCLA researchers pinpointed a new mechanism that potently activates T-cells, the group of white blood cells that play a major role in fighting infections.

26 Mar 2012

OncoSec to present data from head and neck cancer studies at two upcoming conferences

OncoSec Medical Incorporated., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been selected to present data from its Phase III and IV head and neck cancer studies at two upcoming conferences.

23 Mar 2012

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Washington University School of Medicine in St. Louis has received nearly $4.2 million from the Alzheimer's Association to accelerate the launch of the first clinical trials to prevent the symptoms of Alzheimer's disease.

21 Mar 2012

Immunotherapy News and Research

Latest Immunotherapy News and Research

Melanomas express B7-H1 protein to hide from T-cells

Elan first quarter total revenue increases 17% to $288.4 million

OncoSec reports positive interim data from ElectroChemotherapy Phase IV head and neck cancer study

New genetic signature may predict NSCLC patients at risk of relapse

Study demonstrates how Parkinson's disease protein can spread in patient's brain

Immunotherapy may also help elderly cancer patients

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Advaxis, Karolinska Institutet enter collaboration to develop cat allergy vaccine

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Nuvilex realizes important role for Cell-in-a-Box technology

New paradigm for immunotherapy against cancer

Galectin Therapeutics fourth quarter net loss increases to $3.7 million

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

OncoSec Medical closes sale of 31,000,000 shares of common stock in registered public offering

NY-ESO-1 vaccine shows promise against ovarian cancer, melanoma

Intravenous immune globulin effective treatment for GBS, CIDP

OncoSec to purchase $7.75M of securities in registered public offering

Researchers pinpoint new mechanism that potently activates T-cells in leprosy

OncoSec to present data from head and neck cancer studies at two upcoming conferences

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in